• Home
  • Sitemap
  • Help
  • Technical Support
  • Contact
Multidrug Resistance [MDR]
You are here: Product Lines > Cancer > Multidrug Resistance [MDR]
 
Toolbar - View Selection
 
 Items 60-80 of 94 Page 4 of 5 Select Page: << 1 2 3 4 5  >>  
ALX-801-002 Revised 10-Nov-08
Monoclonal Antibody to P-glycoprotein (C219)
Add to Clipboard
SYNONYMS anti-ABCB1 MAb (C219)
anti-CD243 MAb (C219)
PRODUCT LINE Cancer
PRODUCT CATEGORY P-glycoprotein [Pgp] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-002-C100   100 µg 690.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Mouse
Rat
Others
CLONE: C219
ISOTYPE: Mouse IgG1
CONCENTRATION: 0.1mg/ml
FORMULATION: Liquid. In 0.01M PBS containing 1% BSA and 0.1% sodium azide.
IMMUNOGEN: SDS-solubilized plasma membranes of an MDR (multidrug resistant) Chinese hamster ovary (CHO) cell line and a human cell line.
SPECIFICITY: Recognizes an internal, highly conserved amino acid sequence (VQEALD and VQAALD) found in both protein isoforms, P-glycoprotein and MDR3 P-glycoprotein; not species specific.
CROSSREACTIVITY PROTEINS: Cross-reacts with a ~200kDa protein which migrates in the same position as myosin and with C-erbB2 protein (p185c-erbB2).
APPLICATION: Flow Cytometry (cell permeabilization required)
Immunocytochemistry (cytospin preparations)
Immunohistochemistry (frozen sections, paraffin sections)
Immunoprecipitation
Western Blot (1:50-1:100).
Optimal conditions must be determined individually for each application.

Recommendations for Immunohistochemistry on paraffin sections:
- For optimal staining, the sections should be pretreated with an antigen unmasking solution.
- The antibody may be diluted to ≥1:25 for biotin based detection systems.
- For optimal staining, the primary antibody should be incubated 60 minutes at room temperature.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles.
Product Specific Literature References
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies: N. Kartner, et al.; Nature 316, 820 (1985) Abstract
A sensitive method for immunocytochemical detection of P-glycoprotein in multidrug-resistant human ovarian carcinoma cell lines: H.S. Chan, et al.; Lab. Invest. 59, 870 (1988) Abstract
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991) Abstract
Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas: K. Toth, et al.; Am. J. Pathol. 140, 1009 (1992) Abstract
New immunohistochemical "sandwich" staining method for mdr1 P-glycoprotein detection with JSB-1 monoclonal antibody in formalin-fixed, paraffin-embedded human tissues: K. Toth et al.; Am. J. Pathol. 144, 227 (1994) Abstract
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996) Abstract
MRP and MDR1 gene expression in primary breast carcinomas: M. Filipits, et al.; Clin. Cancer Res. 2, 1231 (1996) Abstract
P-glycoprotein expression and prognostic value in acute myeloid leukemia: L. Senent, et al.; Haematologica 83, 783 (1998) Abstract
Transport of doxorubicin in mast cell granules and the effect of the calcium antagonist verapamil: L. Candussio, et al.; Anticancer Res. 19, 1101 (1999) Abstract
Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport: E. Crivellato, et al.; Histochem. J. 31, 635 (1999) Abstract
Clinical significance of P-glycoprotein (P-gp) expression in childhood acute lymphoblastic leukemia. Results of a 6-year prospective study: C. Dhooge & B. De Moerloose; Adv. Exp. Med. Biol. 457, 11 (1999) Abstract
The effects of anticancer drugs in combination with nimodipine and verapamil on cultured cells of glioblastoma multiforme: R. Durmaz, et al.; Clin. Neurol. Neurosurg. 101, 238 (1999) Abstract
Interferon α2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer. Res. Clin. Oncol. 125, 117 (1999) Abstract
A multidrug-resistant breast cancer cell line induced by weekly exposure to doxorubicin: S.M. Hahn, et al.; Int. J. Oncol. 14, 273 (1999) Abstract
Characterization of cyclosporin A transport in cultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin: K. Kawazu, et al.; Invest. Ophtalmol. Vis. Sci. 40, 1738 (1999) Abstract
Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein: J.M. van Den Elsen, et al.; PNAS 96, 13679 (1999) Abstract; Full Text
Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells: H. Wada, et al.; Exp. Hematol. 27, 99 (1999) Abstract
Immunohistochemical evidence that P-glycoprotein in non-small cell lung cancers is associated with shorter survival: H. Yokoyama, et al.; Surg. Today 29, 1141 (1999) Abstract
P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries: M. Demeule, et al.; FEBS Lett. 466, 219 (2000) Abstract
Nucleotide-induced conformational changes in P-glycoprotein and in nucleotide binding site mutants monitored by trypsin sensitivity: M. Julien & P. Gros; Biochemistry 39, 4559 (2000) Abstract
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response: I.O. Ng, et al.; Am. J. Clin. Pathol. 113, 355 (2000) Abstract
Activation of the human P-glycoprotein ATPase by trypsin: S.L. Nuti, et al.; Biochemistry 39, 3424 (2000) Abstract
Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart: A. Rosati, et al.; Anticancer Res. 20, 3403 (2000) Abstract
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000) Abstract; Full Text
Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis: F. Thevenod, et al.; J. Biol. Chem. 275, 1887 (2000) Abstract; Full Text
Characterization of multidrug transporters in a normal renal tubular cell line resistant to doxorubicin. Multidrug transporters in the LLC-PK(1) cell line and its resistant counterpart: G. Decorti, et al.; Biochem. Pharmacol. 61, 61 (2001) Abstract
Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone: R. Yumoto, et al.; Drug. Metab. Dispos. 29, 145 (2001) Abstract; Full Text
Further Categories Containing This Product:
CD Antibodies • Monoclonal Antibodies • Tumor Markers
 
 
ALX-801-001 Revised 22-Feb-05
Monoclonal Antibody to P-glycoprotein (human) (4E3.16)
Add to Clipboard
SYNONYMS anti-ABCB1 (human) MAb (4E3.16)
anti-CD243 (human) MAb (4E3.16)
PRODUCT LINE Cancer
PRODUCT CATEGORY P-glycoprotein [Pgp] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-001-C050   50 µg 790.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: 4E3.16
ISOTYPE: Mouse IgG2a
CONCENTRATION: ~0.05mg/ml
FORMULATION: Liquid. In 0.01M PBS containing 1% BSA and 0.1% sodium azide.
IMMUNOGEN: MDR (multidrug resistant) human squamous lung cancer cell line SW-1573/500 (doxorubicin resistant) and MDR human uterine adenocarcinoma cell line ME180/DOX 500 (doxorubicin resistant).
SPECIFICITY: Recognizes an external epitope of human P-glycoprotein. Does not cross-react with human MDR3 P-glycoprotein.
APPLICATION: Flow Cytometry
Immunocytochemistry
Immunohistochemistry (frozen sections; not recommended for paraffin sections)
Immunoprecipitation.
Note: Not recommended for Western blot.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
POSITIVE CONTROL: Cell lines: Appropriate drug-sensitive parental cell lines and their multidrug resistant derivatives prepared by the same methods as the test specimens can be used as control materials.
Tissue: Liver (positive staining detected along luminal surfaces of bile canaliculi) or colon (positive staining localized to luminal surface of secretory epithelium).
Product Specific Literature References
Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein: R.J. Arceci, et al.; Cancer Res. 53, 310 (1993) Abstract
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996) Abstract
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network: S. Huet, et al.; Cytometry 34, 248 (1998) Abstract
Identification of a multidrug resistance-like system in Tetrahymena pyriformis: evidence for a new detoxication mechanism in freshwater ciliates: M. Bamdad, et al.; FEBS Lett. 456, 389 (1999) Abstract
Discordance of P-glycoprotein expression and function in acute leukemia: B. De Moerloose, et al.; Adv. Exp. Med. Biol. 457, 107 (1999) Abstract
Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines: V. Nuessler, et al.; Leukemia 13, 1864 (1999) Abstract
Conformational heterogeneity of P-glycoprotein: K. Goda, et al.; Cancer Detect. Prevent. 24, 415 (2000) Abstract
Functional characterization of glycosylation-deficient human P-glycoprotein using A vaccinia virus expression system: J.J. Gribar, et al.; J. Membr. Biol. 173, 203 (2000) Abstract
Simultaneous measurement of cellular P-glycoprotein content and function by multiparametric flow-cytometry: M.R. Muller, et al.; Int. J. Clin. Pharmacol. Ther. 38, 180 (2000) Abstract
Further Categories Containing This Product:
CD Antibodies • Monoclonal Antibodies • Tumor Markers
 
 
ALX-801-003 Revised 21-Dec-06
Monoclonal Antibody to P-glycoprotein (human) (C494)
Add to Clipboard
SYNONYMS anti-ABCB1 (human) MAb (C494)
anti-CD243 (human) MAb (C494)
PRODUCT LINE Cancer
PRODUCT CATEGORY P-glycoprotein [Pgp] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-003-C100   100 µg 790.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: C494
ISOTYPE: Mouse IgG2a
SOURCE/HOST: Mouse ascites.
CONCENTRATION: ~0.1mg/ml
FORMULATION: Liquid. In 0.01M PBS containing 1% BSA and 0.1% sodium azide.
IMMUNOGEN: SDS-solubilized plasma membranes of an MDR (multidrug resistant) Chinese hamster ovary cell line and a human leukemic cell line.
SPECIFICITY: Recognizes a gene-specific, internal cellular epitope present only on the human MDR1 isoform of P-glycoprotein. Does not cross-react with human MDR3 P-glycoprotein.
CROSSREACTIVITY PROTEINS: Cross-reacts with pyruvate carboxylase (PC), an abundant mitochondrial enzyme. Unequivocal plasma membrane patterns of immunostaining represent true P-glycoprotein expression. Weak homogeneous, cytoplasmic or granular patterns of reactivity may represent staining of the PC cross-reactive epitope rather than positive staining for P-glycoprotein.
APPLICATION: Flow cytometry (cell permeabilization required):
Tissue culture cell lines, blood or bone marrow may be used. Specimens should be fixed in 3.7% formaldehyde for 10 minutes at room temperature to permeabilize the cell membrane. Incubation with approximately 5-10µg of antibody per 1x106 cells for 30-60 minutes at 4°C is suggested. Secondary antibodies (such as FITC-labelled anti-mouse IgG antibodies) available from commercial suppliers may be used for the subsequent steps, but should be titered in order to optimize the particular protocol in use.

Immunocytochemistry (cytospin preparations),
Immunohistochemistry (frozen sections, paraffin sections):
Adherent cells grown on coverslips or glass slides, cytospin preparations, frozen sections or paraffin-embedded materials may be used. Permeabilization of the cell membrane is a pre-requisite for exposing the epitope recognized by C494.
Frozen sections of cytospin should be air-dried and fixed in acetone for 10 minutes at -20°C.
Paraffin sections should be deparaffinized and rehydrated by conventional means. Secondary antibodies and fluorescent or histochemical detection systems available from other suppliers should be titered for optimal staining. Primary antibody may be diluted to >1:25 for biotin based detection systems. For optimal staining the primary antibody shold be incubated 20-60 minutes at room temperature.

Immunoprecipitation:
The C494 MAb can be used to immunoprecipitate P-glycoprotein from lysates of metabolically or surface radiolabelled cells.

Western Blot:
Protein concentration of specimens used should be in the range of  50-150µg per 50µl. There are many commercially available systems which may be used for direct Western blot. The MAb antibody should be used at a concentration of 1-10µl/ml in indirect Western blots. Exact concentration of antibody and incubation time will vary depending on the particular system used.

Optimal conditions must be determined individually for each application.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -70°C.
Product Specific Literature References
Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies: N. Kartner, et al.; Nature 316, 820 (1985) Abstract
Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies: E. Georges, et al.; PNAS 87, 152 (1990) Abstract; Full Text
Comparison of an immunoperoxidase "sandwich" staining method and western blot detection of P-glycoprotein in human cell lines and sarcomas: K. Toth, et al.; Am. J. Pathol. 140, 1009 (1992) Abstract
MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase: V.V. Rao, et al.; Cancer Res. 54, 1536 (1994) Abstract
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies: F.J. Lacueva, et al.; Histopathology 32, 328 (1998) Abstract
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy: R.E. Jimenez, et al.; Cancer 86, 976 (1999) Abstract
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier: V.V. Rao, et al.; PNAS 96, 3900 (1999) Abstract; Full Text
Multidrug resistance-1 and p-glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance: J.J. Wyman, et al.; J. Orthop. Res. 17, 935 (1999) Abstract
Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response: I.O. Ng, et al.; Am. J. Clin. Pathol. 113, 355 (2000) Abstract
Activation of the human P-glycoprotein ATPase by trypsin: S.L. Nuti, et al.; Biochemistry 39, 3423 (2000) Abstract
Up-regulation of drug resistance-related vaults during dendritic cell development: A.B. Schroeijers, et al.; J. Immunol. 168, 1572 (2002) Abstract
Further Categories Containing This Product:
CD Antibodies • Monoclonal Antibodies • Tumor Markers
 
 
ALX-801-004 Revised 01-Mar-06
Monoclonal Antibody to P-glycoprotein (human) (JSB-1)
Add to Clipboard
SYNONYMS anti-ABCB1 (human) MAb (JSB-1)
anti-CD243 (human) MAb (JSB-1)
PRODUCT LINE Cancer
PRODUCT CATEGORY P-glycoprotein [Pgp] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-004-C125   125 µg 350.00 USD Add To Cart
ALX-801-004-C250   250 µg 630.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
Others
CLONE: JSB-1
ISOTYPE: Mouse IgG1
CONCENTRATION: ~250µg/ml
FORMULATION: Liquid. In serum free culture supernatant containing 0.7% BSA and 0.1% sodium azide.
IMMUNOGEN: MDR (multidrug resistant) Chinese hamster ovary cells (ChrC5).
SPECIFICITY: Recognizes a highly conserved cytoplasmic epitope of the human P-glycoprotein, the expression of which is strongly correlated with the degree of MDR derived MDR cell lines and human MDR cell lines from lung, ovaries and B cell lymphoma. Cross-reacts with Chinese hamster P-glycoprotein. Does not cross-react with mouse, rat or guinea pig P-glycoprotein.
APPLICATION: Flow Cytometry (cell permeabilization required)
Immunocytochemistry (cytospin preparations)
Immunohistochemistry (frozen sections, paraffin sections (weak)).
Recommended starting dilution is 1:20. Optimal conditions must be determined individually for each application.
SHIPPING: SHIPPED ON BLUE ICE
SHORT TERM STORAGE: +4°C
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
Product Images
Please click on thumbnails to enlarge.
Product Specific Literature References
Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies: H. Hamada & T. Tsuruo; PNAS 83, 7785 (1986) Abstract
Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy: W.S. Dalton, et al.; J. Clin. Oncol. 7, 415 (1989) Abstract
Characterization of the human MDR3 P-glycoprotein and its recognition by P-glycoprotein-specific monoclonal antibodies: A.H. Schinkel, et al.; Cancer Res. 51, 2628 (1991) Abstract
Flow cytometric analysis of P-glycoprotein in normal and leukemic cells: M.I. Tiirikainen, et al.; Ann. Hematol. 65, 124 (1992) Abstract
P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy: T.M. Grogan, et al.; Blood 81, 490 (1993) Abstract
Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies: J.L. Gala, et al.; J. Clin. Pathol. 47, 619 (1994) Abstract
Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma: M. Itsubo, et al.; Cancer 73, 298 (1994) Abstract
Relationship of P-glycoprotein and carcinoembryonic antigen expression in human colon carcinoma to local invasion, DNA ploidy, and disease relapse: F.A. Sinicrope, et al.; Cancer 74, 2908 (1994) Abstract
New immunohistochemical "sandwich" staining method for mdr1 P- glycoprotein detection with JSB-1 monoclonal antibody in formalin- fixed, paraffin-embedded human tissues: K. Toth, et al.; Am. J. Pathol. 144, 227 (1994) Abstract
Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome: N. Baldini, et al.; N. Engl. J. Med. 333, 1380 (1995) Abstract
Multidrug resistance P-glycoprotein monoclonal antibody JSB-1 crossreacts with pyruvate carboxylase: V.V. Rao, et al.; J. Histochem. Cytochem. 43, 1187 (1995) Abstract
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy: S. Chevillard, et al.; Cancer 77, 292 (1996) Abstract
Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42: E. Moran, et al.; Eur. J. Cancer 33, 652 (1997) Abstract
Detection of P-glycoprotein in frozen and paraffin-embedded gastric adenocarcinoma tissues using a panel of monoclonal antibodies: F.J. Lacueva, et al.; Histopathology 32, 328 (1998) Abstract
Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival: A.G. Borg, et al.; Br. J. Haematol. 103, 1083 (1998) Abstract
Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovasculature in central nervous system tumors: T. Sawada, et al.; Brain Tumor Pathol. 16, 23 (1999) Abstract
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia: M.R. Grey, et al.; Leuk. Res. 23, 29 (1999) Abstract
Tc-99m MIBI SPECT is useful for noninvasively predicting the presence of MDR1 gene-encoded P-glycoprotein in patients with hepatocellular carcinoma: Y.S. Kim, et al.; Clin. Nucl. Med. 24, 874 (1999) Abstract
Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis: G.A. Meijer, et al.; J. Clin. Pathol. 52, 450 (1999) Abstract
Multidrug resistance phenotype in high grade soft tissue sarcoma: correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy: R.E. Jimenez, et al.; Cancer 86, 976 (1999) Abstract
The stimulatory action of tolbutamide on Ca2+-dependent exocytosis in pancreatic beta cells is mediated by a 65-kDa mdr-like P-glycoprotein: S. Barg, et al.; PNAS 96, 5539 (1999) Abstract; Full Text
Interferon alpha2b differentially affects proliferation of two human renal cell carcinoma cell lines differing in the P-glycoprotein-associated multidrug-resistant phenotype: M.H. Frank & S. Pomer; J. Cancer Res. Clin. Oncol. 125, 117 (1999) Abstract
Assessment of P-glycoprotein expression by immunocytochemistry and flow cytometry using two different monoclonal antibodies coupled with functional efflux analysis in 34 patients with acute myeloid leukemia: S. Poulain, et al.; Adv. Exp. Med. Biol. 457, 57 (1999) Abstract
P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma: A.P. Jillella, et al.; Cancer Invest. 18, 609 (2000) Abstract
Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma: H.M. Coley, et al.; Eur. J. Cancer 36, 881 (2000) Abstract
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies: G.L. Scheffer, et al.; Cancer Res. 60, 5269 (2000) Abstract; Full Text
Further Categories Containing This Product:
CD Antibodies • Monoclonal Antibodies • Tumor Markers
 
 
ALX-801-008 Revised 22-Jul-05
Monoclonal Antibody to P-glycoprotein (human) (MRK16)
Add to Clipboard
SYNONYMS anti-ABCB1 (human) MAb (MRK16)
anti-CD243 (human) MAb (MRK16)
PRODUCT LINE Cancer
PRODUCT CATEGORY P-glycoprotein [Pgp] / Related Products
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-801-008-C150   150 µg 900.00 USD Add To Cart
Product Specification
SPECIES CROSSREACTIVITY:
Human
CLONE: MRK16
ISOTYPE: Mouse IgG2a
CONCENTRATION: 0.5mg/ml.
PURITY DETAIL: Protein A affinity purified.
FORMULATION: Liquid. In PBS containing 1% BSA and 0.1% sodium azide.
IMMUNOGEN: Adriamycin-resistant human myelogenous leukemia K-562/ADM cells.
SPECIFICITY: Recognizes an external epitope of human P-glycoprotein. Also recognizes P-glycoprotein of human cortical adenomas. Does not cross-react with mouse P-glycoprotein.
APPLICATION: Flow Cytometry: For 5x105 pelleted cells use 50µl of 10-100µg/ml.
Immunohistochemistry (frozen sections): 0.1-10µg/ml. Use mild fixation treatment such as 4% paraformaldehyde. Do not use acetone, paraffin, methanol or ethanol as a fixative. Iodine labelling can also  be performed on MRK16.
Immunoprecipitation: 25-50µg/ml
Functional Application: Inhibits P-glycoprotein function.
Note: Not recommended for Western blot (epitope recognized by this antibody may be lost in the presence of protein denaturing agents such as SDS).
SHIPPING: SHIPPED ON BLUE ICE
LONG TERM STORAGE: -20°C
HANDLING: Avoid freeze/thaw cycles.
Product Specific Literature References
Functional role for the 170- to 180-kDa glycoprotein specific to drug- resistant tumor cells as revealed by monoclonal antibodies: H. Hamada and T. Tsuruo; PNAS 83, 7785 (1986) Abstract
A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells: D.J. FitzGerald, et al.; PNAS 84, 4288 (1987) Abstract
Mechanisms of multidrug resistance and implications for therapy: T. Tsuruo; Jpn. J. Cancer Res. 79, 285 (1988) Abstract
Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16: Y. Ishida, et al.; Jpn. J. Cancer Res. 80, 1006 (1989) Abstract
Further characterization of the human adrenal-derived P-glycoprotein recognized by monoclonal antibody MRK 16 reacting with only human P-glycoprotein: I. Sugawara, et al.; Jpn. J. Cancer Res. 80, 1199 (1989) Abstract
Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers: D. Schlaifer, et al.; Br. J. Cancer 62, 177 (1990) Abstract
Detection of multidrug-resistant protein, P-glycoprotein in childhood leukaemia and lymphoma: Y. Mizuno, et al.; Eur. J. Pediatr. 150, 416 (1991) Abstract
Decreased P-glycoprotein expression in multidrug-sensitive and -resistant human myeloma cells induced by the cytokine leukoregulin: C.H. Evans & P.D. Baker; Cancer Res. 52, 5893 (1992) Abstract
Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody: E. Georges, et al.; J. Biol. Chem. 268, 1792 (1993) Abstract; Full Text
Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators: J. Hunter, et al.; J. Biol. Chem. 268, 14991 (1993) Abstract; Full Text
Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model: T. Iwahashi, et al.; Cancer Res. 53, 5475 (1993) Abstract
Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein: A.H. Schinkel, et al.; Int. J. Cancer 55, 478 (1993) Abstract
Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1: T. Hoof, et al.; J. Biol. Chem. 269, 20575 (1994) Abstract; Full Text
In vivo imaging and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [125I]MRK-16 monoclonal antibody: A.M. Scott, et al.; Nucl. Med. Biol. 22, 497 (1995) Abstract
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations: W.T. Beck, et al.; Cancer Res. 56, 3010 (1996) Abstract
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network: S. Huet, et al.; Cytometry 34, 248 (1998) Abstract
The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis: M.J. Smyth, et al.; PNAS 95, 7024 (1998) Abstract; Full Text
Discordance of P-glycoprotein expression and function in acute leukemia: B. De Moerloose, et al.; Adv. Exp. Med. Biol. 457, 107 (1999) Abstract
P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833: M. Egashira, et al.; Blood 93, 599 (1999) Abstract; Full Text
Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier: V.V. Rao, et al.; PNAS 96, 3900 (1999) Abstract; Full Text
Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules: H. Dassow, et al.; Int. J. Clin. Pharmacol. Ther. 38, 209 (2000) Abstract
Conformational heterogeneity of P-glycoprotein: K. Goda, et al.; Cancer Detect. Prev. 24, 415 (2000) Abstract
Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system: J.J. Gribar, et al.; J. Membr. Biol. 173, 203 (2000) Abstract
Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein: F. Ushigome, et al.; Eur. J. Pharmacol. 408, 1 (2000) Abstract
Further Categories Containing This Product:
CD Antibodies • Monoclonal Antibodies • Tumor Markers
 
 
ALX-350-227 Revised 28-Apr-08
Myristicin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Chemopreventive Agents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-227-M100   100 mg 110.00 USD Add To Cart
Product Specification
FORMULA: C11H12O3
MW: 192.2
CAS NUMBER: 607-91-0
MERCK INDEX: 14: 6334
SOURCE/HOST: Isolated from Petroselinium hortense Hoffmann.
PURITY: ≥98% (HPLC)
APPEARANCE: Colorless to slightly yellow liquid.
SOLUBILITY: Soluble in DMSO or methanol.
SHIPPING: AMBIENT
LONG TERM STORAGE: -20°C

Product Description
Natural product isolated from parsley oil. Inducer of glutathione S-transferases. Also inhibits chemical carcinogenesis. Induces rat and human cytochrome P450 enzymes. Has very potent hepatoprotective activity. Induces apoptosis.
Product Specific Literature References
Myristicin: a potential cancer chemopreventive agent from parsley leaf oil: G.-Q. Zheng, et al.; J. Agri. Food Chem. 40, 107 (1992)
Inhibition of benzo[a]pyrene-induced tumorigenesis by myristicin, a volatile aroma constituent of parsley leaf oil: G.-Q. Zheng, et al.; Carcinogenesis 13, 1921 (1992) Abstract
Induction of rat hepatic cytochrome P450 enzymes by myristicin: H.G. Jeong & C.H. Yun; BBRC 217, 966 (1995) Abstract
Toxicological evaluation of myristicin: H. Hallstrom & A. Thuvander; Nat. Toxins 5, 186 (1997), Review Abstract
Roles of human liver cytochrome P450 3A4 and 1A2 enzymes in the oxidation of myristicin: C.H. Yun, et al.; Toxicol. Lett. 137, 143 (2003) Abstract
Hepatoprotective effect of myristicin from nutmeg (Myristica fragrans) on lipopolysaccharide/ d-galactosamine-induced liver injury: T. Morita, et al.; J. Agric. Food Chem. 51, 1560 (2003) Abstract
Myristicin-induced neurotoxicity in human neuroblastoma SK-N-SH cells: B.K. Lee, et al.; Toxicol. Lett. 157, 49 (2005) Abstract
Further Categories Containing This Product:
Antitumor Agents (Enzyme Activators & Inducers) • Cytochrome P450 [CYP450] / Related Products • Glutathione S-Transferase • Active Substances from Fruit and Vegetables • Natural Products - Apoptosis Inducers & Inhibitors • Lipopolysaccharides [LPS] / Related Products
 
 
ALX-350-222 Revised 28-Mar-08
Dihydromyristicin
Add to Clipboard
PRODUCT LINE Natural Products / Antibiotics
PRODUCT CATEGORY Natural Products - Chemopreventive Agents
Ordering Information
Product Numbers: Format: Size: Unit Price: Quantity: Add To Cart
ALX-350-222-M100   100 mg 70.00 USD Add To Cart